Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.79 |
| ▸ | CDK2 | P24941 | 16/20 | 0.67 |
| ▸ | CDK1 | P06493 | 7/20 | 0.60 |
| ▸ | CDK4 | P11802 | 1/20 | 0.55 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248539 | 0.91 | CDK2 (0.68) | KCNH2CDK2CDK1CDK6 | |
| SCHEMBL4248471 | 0.90 | CDK2 (0.79) | KCNH2CDK2CDK1CDK4 | |
| SCHEMBL4243729 | 0.89 | CDK2 (0.66) | KCNH2CDK2CDK1CDK6 | |
| SCHEMBL4245337 | 0.89 | CDK2 (0.79) | KCNH2CDK2CDK1 | |
| SCHEMBL4516013 | 0.88 | KCNH2 (1.00) | KCNH2CDK2CDK1 | |
| SCHEMBL4247837 | 0.81 | CDK2 (0.57) | KCNH2CDK2CDK1CDK4CDK6 | |
| SCHEMBL30828143 | 0.81 | CDK2 (0.83) | KCNH2CDK2CDK1 | |
| SCHEMBL4244145 | 0.81 | CDK2 (0.56) | KCNH2CDK2CDK1CDK6 | |
| SCHEMBL27382932 | 0.81 | CDK2 (0.83) | KCNH2CDK2CDK1 | |
| SCHEMBL4245067 | 0.80 | CDK2 (0.61) | KCNH2CDK2CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | MKI67, TYMP, PCNA | KCNH2 4185/4885CDK2 23/4885CDK1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.